Market
Butterfly Medical raises $21m in funds for BPH device development
Butterfly Medical closed a $21 million Series C funding round to advance development and commercialization of its minimally invasive benign prostatic hyperplasia (BPH) treatment device. The funding supports the company's effort to bring the urology-focused technology to market.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network